Quality medicines for the poor: experience of the Delhi programme on rational use of drugs
Abstract
Prior to 1994, most Delhi hospitals and dispensaries experienced constant shortages of essential medicines. There was erratic prescribing of expensive branded products, frequent complaints about poor drug quality and low patient satisfaction. Delhi took the lead in developing a comprehensive Drug Policy in 1994 and was the only Indian state to have such a comprehensive policy. The policy's main objective is to improve the availability and accessibility of quality essential drugs for all those in need. The Delhi Society for the Promotion of Rational Use of Drugs (DSPRUD), a non-governmental organization, worked in close collaboration with the Delhi Government and with universities to implement various components of the policy. The first Essential Drugs List (EDL) was developed, a centralized pooled procurement system was set up and activities promoting rational use of drugs were initiated. In 1997, the Delhi Programme was designated the INDIA-WHO Essential Drugs Programme by the World Health Organization. The EDL was developed by a committee consisting of a multidisciplinary group of experts using balanced criteria of efficacy, safety, suitability and cost. The first list contained 250 drugs for hospitals and 100 drugs for dispensaries; the list is revised every 2 years. The pooled procurement system, including the rigorous selection of suppliers with a minimum annual threshold turnover and the introduction of Good Manufacturing Practice inspections, resulted in the supply of good quality drugs and in holding down the procurement costs of many drugs. Bulk purchasing of carefully selected essential drugs was estimated to save nearly 30% of the annual drugs bill for the Government of Delhi, savings which were mobilized for procuring more drugs, which in turn improved availability of drugs (more than 80%) at health facilities. Further, training programmes for prescribers led to a positive change in prescribing behaviour, with more than 80% of prescriptions being from the EDL and patients receiving 70-95% of the drugs prescribed. These changes were achieved by changing managerial systems with minimal additional expenditure. The 'Delhi Model' has clearly demonstrated that such a programme can be introduced and implemented and can lead to a better use and availability of medicines.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Delhi's 1997 comprehensive drug policy resulted in 30% savings on the cost of drugs to the Government of Delhi.
“This policy was found to result in 30% savings on the cost of drugs to the Government of Delhi”
Delhi's 1997 comprehensive drug policy increased availability of key drugs from 40% to 70% before implementation to >90% after implementation.
“and to increase the availability of key drugs from 40% to 70% before the policy's implementation to >90% after its implementation.”
Cited by
Sorted by citations
Irving, G., Neves, A. L., Dambha-Miller, H., Oishi, A., Tagashira, H., Verho, A., & Holden, J. (2017) · BMJ Open · doi:10.1136/bmjopen-2017-017902 · Cited by 1,083 · see citing works
Seidman, G., & Atun, R. (2017) · BMJ Global Health · doi:10.1136/bmjgh-2016-000243 · Cited by 133 · see citing works
“In Delhi, India, a 1997 comprehensive drug policy included the development of an Essential Drugs List, a central pooled procurement system and programmatic activities to promote rational drug use.(15) This policy was found to result in 30% savings on the cost of drugs to the Government of Delhi and to increase the ava…”
Background
- Authors
- Roy Chaudhury, R., Parameswar, R., Gupta, U., Sharma, S., Tekur, U., & Bapna, J.
- ORCID
- Sharma, S
- Venue
- Health Policy and Planning
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-03-01
- Volume
- 20
- Issue
- 2
- Pages
- 124-136
- ISSN
- 0268-1080 (ISSN-L)
- 1460-2237
- OpenAlex
- W1975605663
- Cited by
- 81
- References
- 0
- Citations by year
- 2026: 5 · 2025: 7 · 2024: 3 · 2023: 4 · 2022: 6 · 2021: 4 · 2020: 4 · 2019: 2 · 2017: 5 · 2016: 5 · 2015: 6 · 2014: 4 · 2013: 6 · 2012: 4
- FWCI
- 1.64
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Health Policy and Planning (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Social Sciences › Economics, Econometrics and Finance › Finance › Healthcare Systems and Reforms
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pharmaceutical Quality and Counterfeiting
- Keywords
- essential medicines list, drug policy, pooled procurement, drug shortages, drug quality, prescribing behaviour, prescriber education, good manufacturing practices, drug availability, drug costs, Delhi
- MeSH terms
- Formularies as Topic, Health Policy, Humans, India, Poverty, Public Health Administration, Quality Control, Drugs, Essential
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review